The role of extra-cellular adenosine receptors in modulating pain progression during osteoarthritis (OA): A systematic review of the literature

Weaver NC\textsuperscript{a}, Habusta SF\textsuperscript{a} and Raymond RM\textsuperscript{b}

\textsuperscript{a}Department of Orthopedics, Lake Erie College of Osteopathic Medicine, USA
\textsuperscript{b}Department of Physiology, Lake Erie College of Osteopathic Medicine, USA

Abstract

Osteoarthritis: OA continues to be one of the most commonly treated diseases in the United States, resulting in significant financial burden to both patients and healthcare systems. OA is a form of degenerative joint pain caused by progressive destruction within the joints. With the progression of OA, the cartilage, which acts to cushion joints, begins to be eroded, resulting in the destructive rubbing of bone-on-bone. The wear and tear leads to inflammation and pain of the joints. Despite years of clinical experience in treating OA, there remains to be a treatment that adequately alleviates pain, other than complete knee replacement.

Inflammation and pain: Adenosine is an adenine nucleoside that has been reported to be elevated during exercise and inflammation. Adenosine release at inflamed sites contributes to the erythema and resulting increased temperature at the site of inflammation. Experimentally, it was shown that at low adenosine concentrations, inflammation is exaggerated, leading to dramatic swelling, pain, increased blood flow, etc. Data has clearly shown the adenosine's anti-inflammatory actions results from activation of the extracellular adenosine A2A receptors on the vascular endothelium. These data suggest that adenosine, released at inflamed sites, diminishes the swelling that is so prominent at inflamed sites. Recent evidence has suggested that OA is an inflammatory/metabolic disease. Adenosine has been reported to have a bi-modal effect: at low concentrations adenosine acts via specific extracellular adenosine receptors to alleviate pain by acting as an anti-inflammatory agent, however, at relatively higher concentrations, different adenosine receptors are activated and induce pain by becoming cytotoxic. Several reports have suggested that adenosine and/or adenosine deaminase may be used as an early pre-clinical marker of arthritis.

Hypothesis: During the early onset of OA, critical amounts of adenosine are released which act as anti-inflammatory agents. At these low concentrations of adenosine, the anti-inflammatory response is mediated via activation of the extracellular adenosine A2A receptor. Adenosine A1A receptor is also activated, which primarily decreases nerve conduction and metabolism, thereby acting as an anti-nociceptive mediator. Progression of AO leads to downregulation of A1A and A2A and activation of A2B receptors, which progressively increases the pain/inflammation and destruction of joints. Adenosine concentrations or extracellular adenosine receptor activation/deactivation may be early markers for assessing the progressive stage of OA.

Introduction

In 2013 it was estimated that nearly 11.9% of the U.S. population suffered from symptomatic OA [1-4], requiring various surgical interventions [5,6]. Despite the cost to society [7-11] and the potential morbidity and mortality which can result from such invasive surgical procedures, roughly half of all adults diagnosed with knee OA have undergone a total knee replacement during their lifetime [12]. According to the American Academy of Orthopedic Surgery, the standard of care for non-surgical management of progressive OA involve lifestyle changes, which includes weight loss, low impact exercises [13-15], and changes in diet [16]. Patient management also includes oral medical treatments and intra-articular injections of potent anti-inflammatory drugs [10,17] and physical therapy [18]. Although these treatments can be beneficial [10] in treating the symptoms of pain associated with the early stages of OA, the quality of these treatment modalities is largely unpredictable and can develop adverse side effects [19]. These treatments have been shown to be less effective during the late worsening stages of OA [20]. To date, there are no currently known treatments which block the progression of OA, nor the pain associated with this disease [21].

Discussion

Conventional wisdom argues that OA is a weight-bearing disease resulting in progressive and cumulative destruction of articular cartilage which leads to pain [17,20,22]. This progressive and destructive process consists of early cartilage fibrillation with developments to fissuring, ulceration, subchondral sclerosis, joint-space narrowing, and eventual full-thickness loss of hyaline cartilage [4,8,23-25].

Clinical and basic science research suggests that OA is an inflammatory disease much like rheumatoid arthritis [26-28]. There is growing evidence that OA may share several signs and symptoms relating to the metabolic syndrome [29,30], i.e., obesity, hypertension, type 2 diabetes mellitus, and hyperlipidemia [31]. This potential mechanism is substantiated by the fact that there is a high prevalence...
of OA in non-weight bearing joints such as the shoulders and hands [26,32-34]. These clinical data indicate that the etiologies associated with non-weight bearing OA may be multifactorial [12,22,27,33,35,36]. Further evidence demonstrated that the incidence of OA in weight bearing joints does not necessarily increase as weight increases [12], although there is evidence to suggest that knee arthritis may correlate with weight [17]. Evidence has suggested that the severity of pain correlates with the progression of OA, despite the fact that the articular hyaline cartilage, which degenerates over time, is devoid of both neural innervation and vascular supply [20,37,38].

Research has provided evidence that adenosine concentrations, during the early stages of inflammation, [20,39,40] can act as both an analgesic, by combining with the extracellular A1 adenosine receptor, [41] and as an anti-inflammatory response with binding to the A2A adenosine receptor [42,43]. Adenosine has four main extracellular receptors: A1A, A2A, A2B and A3, all of which are G-coupled proteins and each with different functions [24,34,39,44]. The actions of adenosine concentration within specialized tissues and cells have been shown to be related to the interactions of these specific adenosine receptors [39,45]. Experiments have shown that at low concentrations, adenosine primarily binds to the high sensitivity A1 and A2A receptors, resulting in analgesia via increased nociceptor nerve conduction [46] and anti-inflammation by the production of anti-inflammatory mediators [39,43]. Studies utilizing A1 receptor deficient mice recently showed that A1 receptors play a critical role in osteoarthritis development from mononcytic precursors and bone resorption [47,48]. In contrast to A1 adenosine receptors, A2A receptors inhibit osteoclast differentiation and function [42,49] and A2B receptor stimulation has been shown to inhibit wear particle-induced osteolysis, a form of inflammatory bone destruction resulting from particulates shed from joint prostheses [43]. However, adenosine concentrations have a bi-modal effect: at low concentrations adenosine acts as a direct analgesic [41], and anti-inflammatory mediator [39], and at high concentrations, adenosine directly induces pain [20,45,50,51] with pro-inflammatory cytotoxic effects [32,39]. These divergent effects of adenosine have been proposed to be related to the modulation of specific extracellular adenosine receptors [30,39,52-54]. In an unrelated but similar clinical situation, patients suffering from cardiac electrical pathologies, such as supraventricular tachycardia or atrial fibrillation, can be treated by giving an intra-venous bolus injection of adenosine to convert the arrhythmia to sinus rhythm [12,34]. Once administered, patients feel a crushing angina-like chest pain despite the fact that many of these patients do not have a history of coronary artery disease [11,34,55]. These effects are primarily related to the stimulation of different types of extracellular cytotoxic adenosine receptors (i.e., A2B) [56]. During OA, as well as rheumatoid arthritis, recent reports have shown that both adenosine and adenosine deaminase concentrations were increased in serum and knee synovial fluid [39,44]. Adenosine has been reported to induce analgesia during acute inflammation [20,39,41,57]. However, with chronic inflammation, adenosine may induce hyperalgesia [20,51,57]. Adenosine’s metabolic pathway with interactions of specific intracellular and extracellular adenosine receptors may be important for the maintenance of healthy articular cartilage metabolism, as well as being an important analgesic mediator linked to the early phases of OA [24,39,51].

In chronic inflammatory disorders such as rheumatoid arthritis, adenosine and adenosine deaminase were reported to be markedly increased [47]. At increased adenosine concentrations, adenosine was reported to bind to the low sensitivity A2B receptor, resulting in hyperalgesia [20,51]. Binding of adenosine to the low sensitivity A2B receptor inhibits adenosine binding to the A1 and A2A receptors [8,45], thereby removing their analgesic effects.

Abo-Salem, et al. [58] also recognized the hyperalgesic effects of A2B receptor activation. They completed experiments that provided evidence that caffeine, a known analgesic, accomplishes its analgesic effects through binding and blocking the A2B receptor. The A2B receptor activation has also been shown to be cytotoxic at increased adenosine concentrations [50,58], and would therefore be a source of an inflammatory process [59]. Adenosine released at inflamed sites diminishes both the swelling (tumor) leukocyte recruitment and adhesion [60]. Adenosine-activated A2A receptors, has long been known to be a potent vasodilator [61]. These vascular effects of adenosine (A2A) are the basis for pharmacologic stress testing [62]. Adenosine receptor stimulation diminishes neutrophil adhesion to the endothelium by inhibiting both selectin- and integrin-mediated adhesive events [63]. ATP binding to A3 receptor initiates down-regulation or inhibition of A3 receptors, decreasing leukocyte recruitment to sites of bacterial infection [64]. The use of adenosine as an anti-inflammatory agent has remained more of a challenge due to the myriad of other effects adenosine has through stimulation of the A2A and A2B receptor [16,20,30,37,41,49,52-54,65,66]. Interestingly, it is now clear that low-dose methotrexate, the anchor drug for the treatment of rheumatoid arthritis, mediates its anti-inflammatory effects via promotion of adenosine release at inflamed sites [67].

Methotrexate is actively transported into the cell where it is polyglutamated; MTX polyglutamate is a potent inhibitor of AMP deaminase. Accumulation of AICAR, an intermediate metabolite in de novo purine biosynthesis, leads to enhanced release of adenine nucleotides which are released into the extracellular space and converted to adenosine. MTXglu, methotrexate polyglutamates; DHFglu, dihydrofolate polyglutamates; AICAR, aminoimidazole carboxamidoribonucleotide; FAICAR, formyl AICAR; RFC1, reverse folate carrier 1; ADA, adenosine deaminase; AK, adenosine kinase; NTPDase, nucleoside triphosphate phosphohydrolase; ecto-5’NT, ecto-5’nucleotidase (Figure 1).

Non-specific adenosine receptor antagonists, theophylline and caffeine reversed the effect of methotrexate on hind-paw swelling and ankylosis in experimental adjuvant arthritis [67].

Pulsed electromagnetic field technology [68] and scintigraphy [50] have been shown to upregulate the A2A adenosine receptor, known to cause vasodilation [69]. Increased blood flow would not only supply nutrients and oxygen to the tissue but may also increase the delivery of other mediators which serve clinically to aid in tissue repair. Adenosine deaminase (ADA) irreversibly degrades adenosine into inosine, hypoxanthine and xanthine and acts as a homeostatic mechanism to maintain adenosine within the normal physiologic range [69]. Elevated plasma ADA may therefore be an early marker for joint inflammation [8,10,65] and implicate the need for further investigation.

Enohumah and Imarengiaye [20] have broken down the most basic of anatomic structures responsible for pain which include free nerve endings i.e., noceptors. Four different types of nerves have been found to be responsible for nociception in joints [70]. These innervate the joint capsule, subchondral bone, periosteum, ligaments, and menisci [20]. The four different types of noceptor nerves have been termed types I through IV, or A-alpha, A-beta, A-delta, and C [70]. Various structures within the knee, shown to elicit pain during OA, include the fat pads, ligaments, and synovium [20]. All of these studies have confirmed that articular cartilage was not a source of pain. Articular cartilage
receives its nutrition from the synovial fluid in which it is bathed, and is avascular, and lacks the necessary innervations which would be responsible for pain [20]. Essentially, all of the other structures found in the intra-articular space have been identified to have at least types III and IV sensory nerves [20,71]. The fact that intra-articular injection of local anesthetic [72] or removal of intraarticular structures in total knee arthroplasty often result in significant analgesia which provides a rational hypothesis that pain, during the progression of OA, is mainly associated with intraarticular structures [20,50,71,73,74]. Activated subchondral bone [8] nociceptors may be the reason why patient do not receive similar pain reduction following total knee arthroplasty or intraarticular injections which contain a local anesthetic [75].

During the early stages of OA, slight increases in adenosine concentrations (\(A_1\)) bind to the A1 and A2A receptors, acting as an anti-nociceptive (A1) and anti-inflammatory (A2A) agonist (Figure 2) [54,60,64,70]. As OA progresses to the late stage, adenosine concentration increases substantially to activate the low sensitivity A2B receptor. A2B activation inhibits the A1A receptor thereby resulting in pain (Figure 3) [16,30,45,53,66,76].

**Conclusion**

Further investigations are required to determine the role of extracellular adenosine receptors acting as an anti-inflammatory agent during the early stages of OA; the anatomical structure(s) responsible for producing adenosine; and the activation/inactivation of specific extracellular receptors responsible for severe chronic pain. Data from these studies may provide basic clinical treatments for the relief of pain associated with OA. Our hypothesis is during the early phase of OA pain is alleviated in part by adenosine binding the A1A and A2A receptors, which are both low sensitivities.

**References**


70. Lawson SN (2002) Phenotype and function of somatic primary afferent nociceptive neurones with C-, Adelta- or Aalpha/beta-fibres. Exp Physiol 87: 239-244. [Crossref]


Copyright: ©2018 Weaver NC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.